Home > Haematology > EHA 2019 > CASSIOPEIA trial: Phase 3 results of daratumumab + bortezomib/thalidomide/dexamethasone in multiple myeloma

CASSIOPEIA trial: Phase 3 results of daratumumab + bortezomib/thalidomide/dexamethasone in multiple myeloma

Expert
Prof. Phillippe Moreau, University Hospital of Nantes, France
Conference
EHA 2019
Trial
Phase 3, CASSIOPEIA

The addition of daratumumab to the triplet bortezomib, thalidomide, and dexamethasone (VTd) induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma improved both the depth of response and progression-free survival (PFS) compared with VTd alone [1].

Prof. Phillippe Moreau (University Hospital of Nantes, France) discussed the findings from the randomised, open-label, multicentre, phase 3 CASSIOPEIA trial and the potential role for daratumumab in patients with newly diagnosed multiple myeloma in combination with standard-of-care VTd for patients who are candidates for autologous stem cell transplantation (ASCT).

Patients (n=1,085) were enrolled and randomly assigned to VTd induction and consolidation either with (n=543) or without (n=542) the addition of daratumumab (Dara-VTd) followed by high-dose melphalan and ASCT. The stringent complete response ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on